Choose your language

Testimonials from Past Attendees

"TIDES has always been an excellent forum for education."
- Nadim Akhtar, Ph.D., Senior Scientist, Astra Zeneca, United Kingdom

"The TIDES conference is the place to be to learn new technologies related to the peptide industry and to network with some of the world leaders in the field."
- Nicolas Mourier, Ph.D., Director of Product Development, Peptimmune, Inc.

"Year after year TIDES continues the be THE conference that highlights the development of peptide and oligonucleotide therapeutic drugs as well as features the importance of "TIDES" reagents in the diagnostic industry."
- Michael McGinley, Bioseparations Product Manager, Phenomenex

"Given the industry's infancy in developing oligonucleotide therapeutics, the TIDES conference provides an extremely valuable way to stay up to date and interact with colleagues involved with this fast-moving landscape."
- Daren S. Levin, Ph.D., Investigator, Inhaled Product Development, GlaxoSmithKline

Network with Event More Colleagues:

Asia Tides 2010
February 22 - 24, 2010
Sheraton Miyako Hotel · Tokyo,Japan

»  More information on this event

Keynote Presentations:

• Synthetic Biologics: A New Class of Drugs for "Undruggable" Targets
  Gregory L. Verdine, Ph.D., Erving Professor of Chemistry, Harvard University
• RNAi: Developing a New Therapeutic Platform
  John Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
• Non-Coding RNAs as Drug Targets
  Claes Wahlestedt, M.D. Ph.D., Professor, Director of Neuroscience Discovery, The Scripps Research Institute

Confirmed Speakers:
Philip McGurk, Senior Director, Business Development, Pfizer Inc
Axel Ståhlbom, Ph.D., Assessor Biotech, Department of Biotechnology & Pharmacy, Medical Products Agency, Sweden
Paul A. Burke, Ph.D., Executive Director, RNAi Therapeutics, Merck & Co., Inc
Salvatore Bellinvia, M.D., Director, Pharma Division, Giuliani S.p.A., Italy (confirmed)

Featured FDA Presentation:
FDA Perspective on the Development of Peptide-Based Therapeutic Vaccines
Elena Gubina, Ph.D., Expert Biologist, Office of Tissue, Cell and Gene Therapy, CBER, FDA

Including Sessions on:

• Regulatory Updates
• Innovation Showcase
• Manufacturing and Analytical Development
• Updates on Oligonucleotide and Peptide Drug Candidates in Preclinical and Clinical Development
• Formulation and Delivery: Emerging Technologies and Clinical Updates Including Manufacturing Challenges

Plus Pre-Conference Courses

• Current Topics in Oligonucleotide Manufacturing
• Bioanalytical Techniques for Characterization of Peptides and Oligos
• Managing Analytical Development and Quality Control of Oligonucleotides
• Managing Analytical Development and Quality Control of Peptides
• Lead Generation / Hi Throughput Synthesis (tentative)

Featuring New Break-Out Discussion Sessions including small group Q&A sessions with regulators

Nucleic Acids Technologies for Diagnostics Track

• Regulatory Updates
• Analytical Methods and Validation
• Business Considerations
• Case Studies